Canlyniadau Chwilio - Igor Espinoza‐Delgado

  • Dangos 1 - 20 canlyniadau o 20
Mireinio'r Canlyniadau
  1. 1
    Clinical Toxicities of Histone Deacetylase Inhibitors

    Clinical Toxicities of Histone Deacetylase Inhibitors gan Srividya Subramanian, Susan E. Bates, James R. Wright, Igor Espinoza‐Delgado, Richard Piekarz

    Cyhoeddwyd 2010
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Transforming growth factor beta downregulates interleukin-1 (IL-1)- induced IL-6 production by human monocytes

    Transforming growth factor beta downregulates interleukin-1 (IL-1)- induced IL-6 production by human monocytes gan Tiziana Musso, Igor Espinoza‐Delgado, Kari Pulkki, GL Gusella, DL Longo, Luigi Varesio

    Cyhoeddwyd 1990
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    IL-2 up-regulates but IFN-gamma suppresses IL-8 expression in human monocytes.

    IL-2 up-regulates but IFN-gamma suppresses IL-8 expression in human monocytes. gan G. Luca Gusella, Tiziana Musso, Maria Carla Bosco, Igor Espinoza‐Delgado, Koji Matsushima, Luigi Varesio

    Cyhoeddwyd 1993
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Expression and role of p75 interleukin 2 receptor on human monocytes.

    Expression and role of p75 interleukin 2 receptor on human monocytes. gan Igor Espinoza‐Delgado, John R. Ortaldo, Robin Winkler-Pickett, Kazuo Sugamura, Luigi Varesio, D L Longo

    Cyhoeddwyd 1990
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

    Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma gan Suresh S. Ramalingam, Chandra P. Belani, Christopher Ruel, Paul Frankel, Barbara J. Gitlitz, Marianna Koczywas, Igor Espinoza‐Delgado, David R. Gandara

    Cyhoeddwyd 2009
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    A phase 2 study of vorinostat in acute myeloid leukemia

    A phase 2 study of vorinostat in acute myeloid leukemia gan Élise Schaefer, Arturo Loaiza‐Bonilla, Mark Juckett, John F. DiPersio, Vivek Roy, James L. Slack, Wenting Wu, K. M. Laumann, Igor Espinoza‐Delgado, S. D. Gore

    Cyhoeddwyd 2009
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

    Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer gan Suresh S. Ramalingam, Michael L. Maitland, Paul Frankel, Athanassios Argiris, Marianna Koczywas, Barbara J. Gitlitz, Sachdev Thomas, Igor Espinoza‐Delgado, Everett E. Vokes, David R. Gandara, Chandra P. Belani

    Cyhoeddwyd 2009
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer

    A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer gan Marwan Fakih, Lakshmi Pendyala, Gerald J. Fetterly, K. Toth, James A. Zwiebel, Igor Espinoza‐Delgado, Alan Litwin, Youcef M. Rustum, Mary Ellen Ross, Julianne L. Holleran, Merrill J. Egorin

    Cyhoeddwyd 2009
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

    Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors gan Giuseppe Giaccone, Arun Rajan, Arlene Berman, Ronan J. Kelly, Éva Szabó, Ariel López-Chávez, Jane B. Trepel, Min-Jung Lee, Liang Cao, Igor Espinoza‐Delgado, John Spittler, Patrick J. Loehrer

    Cyhoeddwyd 2011
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia

    Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid... gan Ivana Gojo, Ming Tan, Hong‐Bin Fang, Mariola Sadowska, Rena G. Lapidus, Maria R. Baer, France Carrier, Jan H. Beumer, Bean N. Anyang, Rahul Srivastava, Igor Espinoza‐Delgado, Douglas D. Ross

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

    Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma gan Mark Kirschbaum, Paul Frankel, Leslie Popplewell, Jasmine Zain, Maria Delioukina, Vinod Pullarkat, Deron Matsuoka, Bernadette Pulone, A Rotter, Igor Espinoza‐Delgado, Auayporn Nademanee, Stephen J. Forman, David R. Gandara, Edward M. Newman

    Cyhoeddwyd 2011
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study

    Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study gan Anne M. Traynor, Sarita Dubey, Jens C. Eickhoff, Jill Kolesar, Kathleen Schell, Michael S. Huie, David L. Groteluschen, Sarah M. Marcotte, Courtney M. Hallahan, Hilary Weeks, George Wilding, Igor Espinoza‐Delgado, Joan H. Schiller

    Cyhoeddwyd 2009
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)

    A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916) gan Jodi A. Muscal, Patrick A. Thompson, Terzah M. Horton, Ashish M. Ingle, Charlotte H. Ahern, Renee M. McGovern, Joel M. Reid, Matthew M. Ames, Igor Espinoza‐Delgado, Brenda J. Weigel, Susan M. Blaney

    Cyhoeddwyd 2012
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

    Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma gan Ashraf Badros, Angelika M. Burger, Sunita Philip, Rubén Niesvizky, Sarah Kolla, Olga Goloubeva, Carolynn Harris, James A. Zwiebel, James R. Wright, Igor Espinoza‐Delgado, Maria R. Baer, Julianne L. Holleran, Merrill J. Egorin, Steven Grant

    Cyhoeddwyd 2009
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo

    Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo gan B Ramaswamy, Warren Fiskus, Barbara Cohen, C. Pellegrino, Dawn L. Hershman, Ellen Chuang, Thehang Luu, George Somlo, Matthew P. Goetz, Ramona F. Swaby, Charles L. Shapiro, Vered Stearns, PJ Christos, Igor Espinoza‐Delgado, Kapil N. Bhalla, Joseph A. Sparano

    Cyhoeddwyd 2011
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas

    Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas gan Anastasios Stathis, Sébastien J. Hotte, Eric X. Chen, Holger W. Hirte, Amit M. Oza, Patrícia Moretto, Sheila Webster, Anne Laughlin, Lee-Anne Stayner, Shauna McGill, Lisa Wang, Wenjiang Zhang, Igor Espinoza‐Delgado, Julianne L. Holleran, Merrill J. Egorin, Lillian L. Siu

    Cyhoeddwyd 2011
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer

    Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer gan Rosalyn A. Juergens, John Wrangle, Frank P. Vendetti, Sara C. Murphy, Ming Zhao, Barbara Coleman, Rosa Sebree, Kristen Rodgers, Craig M. Hooker, Noreli Franco, Beverly Lee, Salina Tsai, Igor Espinoza Delgado, Michelle A. Rudek, Steven A. Belinsky, James G. Herman, Stephen B. Baylin, Malcolm V. Brock, Charles M. Rudin

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy

    Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy gan Thomas J. Lynch, George R. Blumenschein, Jeffrey A. Engelman, Igor Espinoza‐Delgado, Ramaswamy Govindan, Jeff Hanke, Nasser H. Hanna, John V. Heymach, Fred R. Hirsch, Pasi A. Jänne, Rogério Lilenbaum, Ronald B. Natale, Gregory J. Riely, Lecia V. Sequist, Geoffrey I. Shapiro, Alice T. Shaw, Frances A. Shepherd, Mark A. Socinski, A. Gregory Sorensen, Heather A. Wakelee, Aaron Weitzman

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

    Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies gan Tamer E. Fandy, James G. Herman, Patrick Kerns, Anchalee Jiemjit, Elizabeth A. Sugar, Si-Ho Choi, Allen S. Yang, Timothy Aucott, Tianna Dauses, Rosalie Odchimar-Reissig, Jonathan D. Licht, Melanie J. McConnell, Chris A. Nasrallah, Marianne K. H. Kim, Weijia Zhang, Yezou Sun, Anthony J. Murgo, Igor Espinoza‐Delgado, Katharine Oteiza, Ibitayo Owoeye, Lewis R. Silverman, Steven D. Gore, Hetty E. Carraway

    Cyhoeddwyd 2009
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

    Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03 gan Eudocia Q. Lee, Vinay K. Puduvalli, Joel M. Reid, John G. Kuhn, Kathleen R. Lamborn, Timothy F. Cloughesy, Susan M. Chang, Jan Drappatz, W. K. Alfred Yung, Mark R. Gilbert, H. Ian Robins, Frank S. Lieberman, Andrew B. Lassman, Renee M. McGovern, Jihong Xu, Serena Desideri, Xiabu Ye, Matthew M. Ames, Igor Espinoza‐Delgado, Michael D. Prados, Patrick Y. Wen

    Cyhoeddwyd 2012
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: